Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247789730> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4247789730 endingPage "105" @default.
- W4247789730 startingPage "105" @default.
- W4247789730 abstract "There is an increasing need for third-line treatment regimens in HIV-infected children with antiretroviral treatment (ART) failure. Data are limited on darunavir/ritonavir (DRV/r)-, raltegravir (RAL)- and etravirine (ETR)-containing regimens in treatment-experienced children from resource-constrained settings receiving these drugs as part of routine care.To describe the characteristics and early outcomes of treatment-experienced children (<20 years of age) in the Western Cape Province of South Africa treated with DRV/r-, RAL- or ETR-containing regimens.This was a retrospective review of treatment-experienced children receiving a DRV/r-, RAL- or ETR-containing regimen as recommended by a paediatric expert review committee, based on HIV drug resistance testing.Thirty-five children of median age 8.8 years (interquartile range (IQR) 5.5 - 11) who had received ART for a median of 6.9 years (IQR 5 - 9.9) and started a DRV/r-, RAL- or ETR-containing regimen were included. Before starting such a regimen, the median CD4+ lymphocyte count and HIV-1 RNA level were 405.5 cells/μL (IQR 251.5 - 541) and 28 314 copies/mL (IQR 5 595.5 - 120 186.5) (log 4.5 (IQR 3.7 - 5)), respectively, in 24 subjects with available results. After a median of 2 years (IQR 1.3 - 4) on treatment, 29/30 (96.7%) and 23/30 (76.7%) subjects with available results had HIV-1 RNA levels of <400 and <50 copies/mL, respectively.This study found DRV/r-, RAL- and ETR-containing regimens to be effective in a group of treatment-experienced children and adolescents with multidrug-resistant HIV. Although the treatment regimens in this study were individualised based on HIV genotyping results, further research evaluating the safety and efficacy of standardised third-line treatment regimens in children of all ages is needed." @default.
- W4247789730 created "2022-05-12" @default.
- W4247789730 creator A5004487706 @default.
- W4247789730 creator A5084792779 @default.
- W4247789730 date "2018-02-01" @default.
- W4247789730 modified "2023-09-25" @default.
- W4247789730 title "Characteristics and early outcomes of children and adolescents treated with darunavir/ritonavir-, raltegravir- or etravirine-containing antiretroviral therapy in the Western Cape Province of South Africa" @default.
- W4247789730 doi "https://doi.org/10.7196/samj.2017.v108i2.12573" @default.
- W4247789730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29429441" @default.
- W4247789730 hasPublicationYear "2018" @default.
- W4247789730 type Work @default.
- W4247789730 citedByCount "2" @default.
- W4247789730 countsByYear W42477897302019 @default.
- W4247789730 countsByYear W42477897302020 @default.
- W4247789730 crossrefType "journal-article" @default.
- W4247789730 hasAuthorship W4247789730A5004487706 @default.
- W4247789730 hasAuthorship W4247789730A5084792779 @default.
- W4247789730 hasBestOaLocation W42477897301 @default.
- W4247789730 hasConcept C119060515 @default.
- W4247789730 hasConcept C126322002 @default.
- W4247789730 hasConcept C142462285 @default.
- W4247789730 hasConcept C187212893 @default.
- W4247789730 hasConcept C197934379 @default.
- W4247789730 hasConcept C203014093 @default.
- W4247789730 hasConcept C2777182164 @default.
- W4247789730 hasConcept C2778375690 @default.
- W4247789730 hasConcept C2779182219 @default.
- W4247789730 hasConcept C2779298103 @default.
- W4247789730 hasConcept C2780345285 @default.
- W4247789730 hasConcept C2780404665 @default.
- W4247789730 hasConcept C2781413609 @default.
- W4247789730 hasConcept C2993143319 @default.
- W4247789730 hasConcept C3013748606 @default.
- W4247789730 hasConcept C71924100 @default.
- W4247789730 hasConceptScore W4247789730C119060515 @default.
- W4247789730 hasConceptScore W4247789730C126322002 @default.
- W4247789730 hasConceptScore W4247789730C142462285 @default.
- W4247789730 hasConceptScore W4247789730C187212893 @default.
- W4247789730 hasConceptScore W4247789730C197934379 @default.
- W4247789730 hasConceptScore W4247789730C203014093 @default.
- W4247789730 hasConceptScore W4247789730C2777182164 @default.
- W4247789730 hasConceptScore W4247789730C2778375690 @default.
- W4247789730 hasConceptScore W4247789730C2779182219 @default.
- W4247789730 hasConceptScore W4247789730C2779298103 @default.
- W4247789730 hasConceptScore W4247789730C2780345285 @default.
- W4247789730 hasConceptScore W4247789730C2780404665 @default.
- W4247789730 hasConceptScore W4247789730C2781413609 @default.
- W4247789730 hasConceptScore W4247789730C2993143319 @default.
- W4247789730 hasConceptScore W4247789730C3013748606 @default.
- W4247789730 hasConceptScore W4247789730C71924100 @default.
- W4247789730 hasIssue "2" @default.
- W4247789730 hasLocation W42477897301 @default.
- W4247789730 hasLocation W42477897302 @default.
- W4247789730 hasOpenAccess W4247789730 @default.
- W4247789730 hasPrimaryLocation W42477897301 @default.
- W4247789730 hasRelatedWork W2013830391 @default.
- W4247789730 hasRelatedWork W2045730529 @default.
- W4247789730 hasRelatedWork W2090886797 @default.
- W4247789730 hasRelatedWork W2282180943 @default.
- W4247789730 hasRelatedWork W2752149978 @default.
- W4247789730 hasRelatedWork W2985718649 @default.
- W4247789730 hasRelatedWork W3141735964 @default.
- W4247789730 hasRelatedWork W814398871 @default.
- W4247789730 hasRelatedWork W2538620985 @default.
- W4247789730 hasRelatedWork W2592802524 @default.
- W4247789730 hasVolume "108" @default.
- W4247789730 isParatext "false" @default.
- W4247789730 isRetracted "false" @default.
- W4247789730 workType "article" @default.